Online Webinar 2019 - Live Webinar How to Detect Lack of Data Integrity
Topics/Call fo Papers
Overview
Data are central to the development, manufacture and marketing of pharmaceuticals of all types. The renewed interest in data integrity raises questions regarding what is data integrity and how to assess it. Lack of data integrity comes in two forms: purposeful manipulation of the data to deceive and the inadvertent problems that occur in the production and analysis of data. Humans, equipment or both can be the source of the problem. This session discusses both types of data integrity sources and introduces the assessment of “data pedigree” as a concept that puts focus on the types of data integrity issues and analytical and statistical methods for detecting data problems. Pharma and biotech case studies are used throughout the presentation to illustrate how the various approaches together.
Session Highlights
What is data integrity; what does it look like
Case studies illustrating types and sources of data integrity issues
Procedures for assessing data pedigree, integrity and quality
Computer, analytical and statistical methods for evaluating data integrity and quality
Limitations of observational data
Guiding principles, tips and traps for the effective data integrity assessment
Why Should you Attend
Data are central to the development, manufacture and marketing of pharmaceuticals of all types. The renewed interest in data integrity raises questions regarding what is data integrity and how to assess it. Lack of data integrity comes in two forms: purposeful manipulation of the data to deceive and the inadvertent problems that occur in the production and analysis of data. Humans, equipment or both can be the source of the problem. This session discusses both types of data integrity sources and introduces the assessment of 'data pedigree' as a concept that puts focus on the types of data integrity issues and analytical and statistical methods for detecting data problems. Pharma and biotech case studies are used throughout the presentation to illustrate the various approaches.
Who will Benefit
Senior management
Quality Assurance Team Members
Quality Control Team Members
Compliance Auditors
Process Development Team Members
Supply Chain and Logistics Managers
Regulatory Affairs Team Members
Engineering Staff
IT Management and Staff working in regulated areas
Speaker
Ron Snee is the Founder and President of Snee Associates, a firm dedicated to successful implementation of process and organizational improvement initiatives. He provides guidance to senior executives in their pursuit of improved business performance using Quality by Design, Lean Six Sigma and other approaches that produce bottom line results. He has played a leadership role in 32 major improvement initiatives for firms such as Novartis, Schering Plough, Human Genome Sciences, Boehringer-Ingelheim and Kraft Foods. Prior to his consulting career he spent 24 years at the DuPont Company in a variety of assignments including pharmaceutical clinical trial design and analysis. He has developed and applied process design, improvement, monitoring and control methodologies for more than 30 years.
His recent application and research on QbD has produced eight articles on use of QbD in Pharma and Biotech. He has also coauthored 2 books on the methods and tools of QbD and speaks regularly at conferences and meetings on the subject. He is a frequent speaker and has published 5 books and more than 300 papers in the fields of performance improvement, quality, management, and statistics. He is a past recipient of the Institute of Validation Technology Speaker of the Year Award.
Data are central to the development, manufacture and marketing of pharmaceuticals of all types. The renewed interest in data integrity raises questions regarding what is data integrity and how to assess it. Lack of data integrity comes in two forms: purposeful manipulation of the data to deceive and the inadvertent problems that occur in the production and analysis of data. Humans, equipment or both can be the source of the problem. This session discusses both types of data integrity sources and introduces the assessment of “data pedigree” as a concept that puts focus on the types of data integrity issues and analytical and statistical methods for detecting data problems. Pharma and biotech case studies are used throughout the presentation to illustrate how the various approaches together.
Session Highlights
What is data integrity; what does it look like
Case studies illustrating types and sources of data integrity issues
Procedures for assessing data pedigree, integrity and quality
Computer, analytical and statistical methods for evaluating data integrity and quality
Limitations of observational data
Guiding principles, tips and traps for the effective data integrity assessment
Why Should you Attend
Data are central to the development, manufacture and marketing of pharmaceuticals of all types. The renewed interest in data integrity raises questions regarding what is data integrity and how to assess it. Lack of data integrity comes in two forms: purposeful manipulation of the data to deceive and the inadvertent problems that occur in the production and analysis of data. Humans, equipment or both can be the source of the problem. This session discusses both types of data integrity sources and introduces the assessment of 'data pedigree' as a concept that puts focus on the types of data integrity issues and analytical and statistical methods for detecting data problems. Pharma and biotech case studies are used throughout the presentation to illustrate the various approaches.
Who will Benefit
Senior management
Quality Assurance Team Members
Quality Control Team Members
Compliance Auditors
Process Development Team Members
Supply Chain and Logistics Managers
Regulatory Affairs Team Members
Engineering Staff
IT Management and Staff working in regulated areas
Speaker
Ron Snee is the Founder and President of Snee Associates, a firm dedicated to successful implementation of process and organizational improvement initiatives. He provides guidance to senior executives in their pursuit of improved business performance using Quality by Design, Lean Six Sigma and other approaches that produce bottom line results. He has played a leadership role in 32 major improvement initiatives for firms such as Novartis, Schering Plough, Human Genome Sciences, Boehringer-Ingelheim and Kraft Foods. Prior to his consulting career he spent 24 years at the DuPont Company in a variety of assignments including pharmaceutical clinical trial design and analysis. He has developed and applied process design, improvement, monitoring and control methodologies for more than 30 years.
His recent application and research on QbD has produced eight articles on use of QbD in Pharma and Biotech. He has also coauthored 2 books on the methods and tools of QbD and speaks regularly at conferences and meetings on the subject. He is a frequent speaker and has published 5 books and more than 300 papers in the fields of performance improvement, quality, management, and statistics. He is a past recipient of the Institute of Validation Technology Speaker of the Year Award.
Other CFPs
- Live Webinar Understanding the FDA Compounding Pharmacies Guidance Document
- How to prepare for and host a FDA inspection and respond to 483’s
- 2 Days seminar Assuring Data Integrity in the Life Science industry
- 3-Hours Live Webinar on Harmonized Tariff Schedule/Schedule B Classification
- 8th SEHA International Nursing, Midwifery and Allied Health Conference
Last modified: 2019-06-27 15:00:58